Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors

被引:89
|
作者
Young, MB
Barrow, JC
Glass, KL
Lundell, GF
Newton, CL
Pellicore, JM
Rittle, KE
Selnick, HG
Stauffer, KJ
Vacca, JP
Williams, PD
Bohn, D
Clayton, FC
Cook, JJ
Krueger, JA
Kuo, LC
Lewis, SD
Lucas, BJ
McMasters, DR
Miller-Stein, C
Pietrak, BL
Wallace, AA
White, RB
Wong, B
Yan, YW
Nantermet, PG
机构
[1] Merck & Co Inc, Merck Res Labs, Med Chem, West Point, PA 19486 USA
[2] Merck & Co Inc, Merck Res Labs, Pharmacol, West Point, PA 19486 USA
[3] Merck & Co Inc, Merck Res Labs, Biol Chem, West Point, PA 19486 USA
[4] Merck & Co Inc, Merck Res Labs, Struct Biol, West Point, PA 19486 USA
[5] Merck & Co Inc, Merck Res Labs, Mol Syst, West Point, PA 19486 USA
[6] Merck & Co Inc, Merck Res Labs, Drug Metab, West Point, PA 19486 USA
关键词
D O I
10.1021/jm030303e
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In an effort to discover potent, clinically useful thrombin inhibitors, a rapid analogue synthetic approach was used to explore the P-1 region. Various benzylamines were coupled to a pyridine/pyrazinone P-2-P-3 template. One compound with an o-thiadiazole benzylic substitution was found to have a thrombin K-i of 0.84 nM. A study of ortho-substituted five-membered-ring heterocycles was undertaken and subsequently demonstrated that the o-triazole and tetrazole rings were optimal. Combination of these potent P-1 aryl heterocycles with a variety of P-2-P-3 groups produced a compound with an extraordinary thrombin inhibitory activity of 1.4 pM. It is hoped that this potency enhancement in P-1 will allow for more diversification in the P-2-P-3 region to ultimately address additional pharmacological concerns.
引用
收藏
页码:2995 / 3008
页数:14
相关论文
共 50 条
  • [31] Design of P1′ and P3′ residues of trivalent thrombin inhibitors and their crystal structures
    Sion-Usakiewicz, JJ
    Sivaraman, J
    Li, YG
    Cygler, M
    Konishi, Y
    BIOCHEMISTRY, 2000, 39 (09) : 2384 - 2391
  • [32] The synthesis and evaluation of cyclic ureas as HIV protease inhibitors:: Modifications of the P1/P1′ residues
    Patel, M
    Bacheler, LT
    Rayner, MM
    Cordova, BC
    Klabe, RM
    Erickson-Viitanen, S
    Seitz, SP
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (07) : 823 - 828
  • [33] Synthesis and evaluation of potent human immunodeficiency virus 1 protease inhibitors with epimeric isopropanol as novel P1′ ligands
    Zhu, Mei
    Ma, Ling
    Dong, Biao
    Zhang, Guoning
    Wang, Juxian
    Zhou, Jinming
    Cen, Shan
    Wang, Yucheng
    FUTURE MEDICINAL CHEMISTRY, 2020, 12 (09) : 775 - 794
  • [34] Synthesis of heterocycle-based selective inhibitors of neuronal nitric oxide synthase with improved pharmacokinetic properties
    Lawton, Graham R.
    Ji, Haitao
    Silverman, Richard B.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 567 - 567
  • [35] Proteinase inhibitors from desert locust, Schistocerca gregaria:: engineering of both P1 and P1′ residues converts a potent chymotrypsin inhibitor to a potent trypsin
    Malik, Z
    Amir, S
    Pál, G
    Buzás, Z
    Varallyay, É
    Antal, J
    Szilágyi, Z
    Vékey, K
    Asbóth, B
    Patthy, A
    Gráf, L
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1999, 1434 (01): : 143 - 150
  • [36] Potent and selective TF/FVIIa inhibitors containing a neutral P1 ligand
    Miura, Masanori
    Seki, Norio
    Koike, Takanori
    Ishihara, Tsukasa
    Niimi, Tatsuya
    Hirayama, Fukushi
    Shigenaga, Takeshi
    Sakai-Moritani, Yumiko
    Kawasaki, Tomihisa
    Sakamoto, Shuichi
    Okada, Minoru
    Ohta, Mitsuaki
    Tsukamoto, Shin-ichi
    BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (23) : 7688 - 7705
  • [37] Design, synthesis, and biological evaluation of fused heterocycle-based beta-amino amides as potent, orally active DPP-IV inhibitors for the treatment of type 2 diabetes
    Kowalchick, JE
    Kim, D
    Wang, LP
    Beconi, M
    Eiermann, G
    He, HB
    Leiting, B
    Lyons, KA
    Patel, RA
    Patel, SB
    Petrov, A
    Scapin, G
    Wu, JK
    Thornberry, NA
    Weber, AE
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2673 - U2674
  • [38] STRUCTURE-FUNCTION ASPECTS OF NEUTRAL P1 RESIDUE PEPTIDE INHIBITORS OF THROMBIN
    DEADMAN, J
    CLAESON, G
    SCULLY, MF
    JOURNAL OF ENZYME INHIBITION, 1995, 9 (01): : 29 - 41
  • [39] Noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at P1
    Lee, K
    Jung, WH
    Park, CW
    Park, HD
    Lee, SH
    Kwon, OH
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (07) : 1017 - 1022
  • [40] Potent thrombin inhibitors that probe the S-1' subsite: Tripeptide transition state analogues based on a heterocycle-activated carbonyl group
    Costanzo, MJ
    Maryanoff, BE
    Hecker, LR
    Schott, MR
    Yabut, SC
    Zhang, HC
    AndradeGordon, P
    Kauffman, JA
    Lewis, JM
    Krishnan, R
    Tulinsky, A
    JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (16) : 3039 - 3043